MarketPulse

convertible notes offering

4 articles
BenzingaBenzinga··Lekha Gupta

Nebius Eyes Profitability in 2027 as BofA Initiates $150 Price Target

Bank of America initiates coverage of $NBIS with Buy rating and $150 price target, forecasting operating margin inflection by FY27 amid explosive AI infrastructure growth.
NBISAI infrastructureoperating margins
The Motley FoolThe Motley Fool··David Jagielski, Cpa

CRISPR Therapeutics Stock Slumps 9% Despite Casgevy Approval and Strong Cash Position

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.
VRTXCRSPgene editingCasgevy
BenzingaBenzinga··Lekha Gupta

Nebius Shares Fall 3.34% as $4.55B Convertible Offering Closes Amid Market Weakness

Nebius Group shares fell 3.34% Monday following successful $4.55B convertible notes offering close amid broader market weakness.
NBISrevenue guidancemarket decline
BenzingaBenzinga··Lekha Gupta

Nebius Shares Slip 3% as Growth Stock Selloff Overshadows AI Expansion Plans

Nebius shares fell 3% Thursday amid growth stock weakness, despite pricing a $4B convertible offering and announcing a NVIDIA enterprise partnership.
NVDAMSFTNBISAI infrastructuretechnical analysis